Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr 14;4(6):438.
doi: 10.4022/jafib.438. eCollection 2012 Apr-May.

Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation

Affiliations
Review

Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation

Jeff M Berry et al. J Atr Fibrillation. .

Abstract

Cardiac resynchronization therapy (CRT) has evolved as an effective therapy for patients with congestive heart failure (CHF) and ventricular dyssynchrony, currently defined as a wide QRS on the electrocardiogram. While multiple randomized controlled trials have confirmed the favorable effects of CRT on mortality and heart failure symptoms for patients in sinus rhythm, only recently observational studies have begun to suggest a similar benefit for patients with atrial fibrillation (AF) and dyssynchrony. Yet, implementing effective biventricular pacing in patients with AF can be problematic due to competing intrinsic AV conduction. For patients with depressed ejection fractions needing AV node (AVN) ablation to control fast ventricular rates, biventricular pacing has been shown to be superior to right ventricular pacing alone. When consistent pacing (over 90% of the time) cannot be achieved in AF patients due to a rapid ventricular response despite pharmacological therapy, AVN ablation should be considered. The additional benefit of performing AVN ablation to promote biventricular pacing in patients without rapid ventricular rates remains uncertain. A randomized controlled trial is needed to test the incremental benefit of AVN ablation to promote biventricular pacing in heart failure patients with AF and wide QRS.

PubMed Disclaimer

Similar articles

References

    1. Roger Véronique L, Go Alan S, Lloyd-Jones Donald M, Adams Robert J, Berry Jarett D, Brown Todd M, Carnethon Mercedes R, Dai Shifan, de Simone Giovanni, Ford Earl S, Fox Caroline S, Fullerton Heather J, Gillespie Cathleen, Greenlund Kurt J, Hailpern Susan M, Heit John A, Ho P Michael, Howard Virginia J, Kissela Brett M, Kittner Steven J, Lackland Daniel T, Lichtman Judith H, Lisabeth Lynda D, Makuc Diane M, Marcus Gregory M, Marelli Ariane, Matchar David B, McDermott Mary M, Meigs James B, Moy Claudia S, Mozaffarian Dariush, Mussolino Michael E, Nichol Graham, Paynter Nina P, Rosamond Wayne D, Sorlie Paul D, Stafford Randall S, Turan Tanya N, Turner Melanie B, Wong Nathan D, Wylie-Rosett Judith. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 01;123 (4):e18–e209. - PMC - PubMed
    1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 1991 Aug 01;325 (5):293–302. - PubMed
    1. Pitt B, Zannad F, Remme W J, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999 Sep 02;341 (10):709–17. - PubMed
    1. Pfeffer M A, Braunwald E, Moyé L A, Basta L, Brown E J, Cuddy T E, Davis B R, Geltman E M, Goldman S, Flaker G C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992 Sep 03;327 (10):669–77. - PubMed
    1. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus K L, Jánosi A, Thorgeirsson G, Dunselman P H, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000 Mar 08;283 (10):1295–302. - PubMed

LinkOut - more resources